Different phenotypes of the NAT2 gene influences hydralazine antihypertensive response in patients with resistant hypertension

Pharmacogenomics

Volumn 15, Issue 2, 2014, Pages 169-178

  Spinasse, Lizania Borges ^a   Santos, Adalberto Rezende ^a   Suffys, Philip Noel ^a   Muxfeldt, Elizabeth Silaid ^b   Salles, Gil Fernando ^b  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Brazilian population; hydralazine; NAT2 polymorphism; resistant hypertension; SNP

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ARYLAMINE ACETYLTRANSFERASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDRALAZINE; ANTIHYPERTENSIVE AGENT; NAT2 PROTEIN, HUMAN;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BRAZIL; CASE CONTROL STUDY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DNA DETERMINATION; DRUG ACETYLATION; DRUG RESPONSE; DRUG SUBSTITUTION; FEMALE; GENE SEQUENCE; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; LUPUS LIKE SYNDROME; MAJOR CLINICAL STUDY; MALE; NAT2 GENE; NUCLEOTIDE SEQUENCE; PHENOTYPE; RESISTANT HYPERTENSION; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT; ACETYLATION; AGED; BLOOD PRESSURE; DRUG EFFECTS; GENETIC POLYMORPHISM; GENETICS; HYPERTENSION; MIDDLE AGED; PATHOLOGY;

ACETYLATION; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; ARYLAMINE N-ACETYLTRANSFERASE; BLOOD PRESSURE; FEMALE; HUMANS; HYDRALAZINE; HYPERTENSION; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, GENETIC;

EID: 84893068653     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.202     Document Type: Article

References (27)

1. Glavnik N, Petrovic D. M235T polymorphism of the angiotensinogen gene and insertion/deletion polymorphism of the angiotensin-1 converting enzyme gene in essential arterial hypertension in Caucasians. Folia Biol. 53, 69-70 (2007).
2. Petrovic D. Association of the-262C/T polymorphism in the catalase gene promoter and the C242T polymorphism of the NADPH oxidase P22phox gene with essential arterial hypertension in patients with diabetes mellitus Type 2. Clin. Exp. Hypertens. doi:10.3109/106 41963.2013.783051 (2013) (Epub ahead of print).
3. Calhoun DA, Jones D, Textor S et al. Resistant hypertension: Diagnosis, evaluation, and treatment: A scientific statement from the American heart association professional education committee of the council for high blood pressure research. Circulation 117, 510-526 (2008).
4. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 57, 1076-1080 (2011).
5. Egan BM, Zhao Y, Axon N, Brzezinski WA, Ferdinand KC. Uncontrolled apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation 124, 1046-1058 (2011).
6. Muxfeldt ES, de Souza F, Salles GF. Resistant hypertension: A practical clinical approach. J. Hum. Hypertens. 27(11), 657-662 (2013).
7. Salles GF, Cardoso CRL, Muxfeldt ES. Prognostic influence of office and ambulatory blood pressure in resistent hypertension. Arch. Intern. Med. 168, 2340-2346 (2008).
8. De Souza F, Muxfeldt ES, Fiszman R, Salles GF. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension 55, 147-152 (2010).
9. Kandler MR, Mah GT, Tejani AM, Stabler SN, Salzwedel DM. Hydralazine for essential hypertension. Cochrane Database Syst. Rev. 9, CD004934 (2011).
10. Shepherd AM, McNay JL, Ludden TM, Lin MS, Musgrave GE. Plasma concentration and acetylator phenotype determine response to oral hydralazine. Hypertension 3, 580-585 (1981).
11. Ladero JM. Influence of polymorphic N-acetyltransferases on non-malignant spontaneous disorders and on response to drugs. Curr. Drug Metab. 9, 532-537 (2008).
12. Agundez JA. Polymorphisms of human N-acetyltransferases and cancer acetylation polymorphisms. Cancer Epidemiol. Biomark. Prev. 9, 29-42 (2000).
13. Hein DW, Doll MA. Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes. Pharmacogenomics 13, 31-41 (2012).
14. Sim E, Walters K, Boukouvala S. Arylamine N-acetytransferases: From structure to function. Drug Metab. Rev. 40, 479-510 (2008).
15. Teixeira RL, Silva FP, Silveira AR et al. Sequence analysis of NAT2 gene in Brazilians: Identification of undescribed single nucleotide polymorphisms and molecular modeling of the N-acetyltransferase 2 protein structure. Mutat. Res. 683, 43-49 (2010).
16. Teixeira RL, Miranda AB, Pacheco AG et al. Genetic profile of the arylamine N-acetytransferase 2 coding gene among individuals from two different regions of Brazil. Mutat. Res. 624, 31-40 (2007).
17. Li N, Stephens M. Modeling linkage disequilibrium and identifying recombination hotspots using nucleotide polymorphism data. Genetics 165, 2213-2233 (2003).
18. Stephens M, Donnelly P. A comparison of Bayesian methods for haplotype reconstruction. Am. J. Hum. Genet. 73, 1162-1169 (2003).
19. Walker K, Ginsberg G, Hattis D, Johns DO, Guyton KZ, Sonawane B. Genetic polymorphism in N-acetyltransferase (NAT): Population distribution of NAT1 and NAT2 activity. J. Toxicol. Environ. Health B Crit. Rev. 12, 440-472 (2009).
20. Malik MA, Upadhyay R, Modi DR, Zargar SA, Mittal B. Association of NAT2 gene polymorphisms with susceptibility to esophageal and gastric cancers in the Kashmir valley. Arch. Med. Res. 40, 416-423 (2009).
21. Kozhekbaeva ZHM, Gra OA, Fadeev VS et al. Association of NAT2 polymorphisms with susceptibility to psoriasis in the Moscow population. Mol. Biol. 43, 62-76 (2009).
22. Sabbagh A, Darlu P, Crouau-Roy B, Poloni ES. Arylamine N-acetyltransferase 2 (NAT2) genetic diversity and traditional subsistence: A worldwide population survey. PLoS ONE 6(4), e18507 (2011).
23. Pritchard JK, Pickrell JK, Coop G. The genetics of human adaptation: Hard sweeps, soft sweeps, and polygenic adaptation. Curr. Biol. 20, R208-R215 (2010).
24. Magalon H, Patin E, Austerlitz F et al. Population genetic diversity of the NAT2 gene supports a role of acetylation in human adaptation to farming in central Asia. Eur. J. Hum. Genet. 16, 243-251 (2008).
25. McVicker G, Gordon D, Davis C, Green P. Widespread genomic signatures of natural selection in hominid evolution. PLoS Genet. 5, e1000471 (2009).
26. Yokogawa N, Vivino F. Hydralazine-induced autoimmune disease: Comparison to idiopathic lupus and ANCA-positive vasculitis. Mod. Rheumatol. 19, 338-347 (2009).
27. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC guidelines for the management of arterial hypertension. The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 31, 1281-1357 (2013).